NCT05302843View on ClinicalTrials.gov

A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 22, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Metastasis, Neoplasm
Interventions
DRUG

BPI-28592

Characterize the pharmacokinetics (PK)，safety，antitumor activity of BPI-28592

Trial Locations (1)

Unknown

RECRUITING

Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine, Hangzhou

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY